Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace Holdings (MEDP) will release its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. A conference call to discuss the results will take place on Thursday, October 22, 2026, at 9:00 a.m. ET, with advance registration required for telephone participants. A live webcast, replay, and supplemental slide presentation will be available through the Investors section of the company’s website.
Innventure (NASDAQ: INV) announced several governance and leadership changes to enhance board independence and oversight. Lead Independent Director Bruce Brown was unanimously elected independent Chairman on August 27, 2026, succeeding Michael Otworth. Independent Director Catriona Fallon, who joined the board in June 2026, was appointed Audit Committee Chair on August 11, 2026.
The company said these moves align with its efforts to strengthen accountability as it reduces parent-level spending, evaluates funding alternatives, and assesses strategic options for the AeroFlexx business. Dr. William Grieco’s succession as CEO and director, originally planned for October 1, 2026, has been accelerated to September 1, 2026, replacing Bill Haskell and filling his board vacancy. To further bolster independence, management director Suzanne Niemeyer resigned from the board effective August 31, 2026, and the board size was reduced to eight directors. Innventure also launched an ongoing search for a new Chief Financial Officer as it considers additional organizational changes.
Medpace (Nasdaq: MEDP) reported second quarter 2026 revenue of $707.3 million, up 17.2% year over year, with a backlog conversion rate of 24.1%. Net new business awards rose to $795.7 million, up 28.2%, yielding a net book-to-bill ratio of 1.13x and backlog of $3,014.2 million, up 4.9%.
GAAP net income for Q2 2026 was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10, a year earlier, with net income margin improving to 17.2%. EBITDA increased 17.6% to $153.4 million (21.7% margin). Year-to-date, revenue reached $1,413.9 million, GAAP net income $245.2 million ($8.53 diluted EPS), and EBITDA $302.8 million (21.4% margin). Medpace ended June 30, 2026 with $502.7 million in cash, generated $162.0 million in Q2 operating cash flow, repurchased 705,616 shares for $294.7 million, and had $527.0 million remaining under its buyback authorization. 2026 guidance calls for revenue of $2.805–$2.885 billion, GAAP net income of $494.0–$514.0 million, EBITDA of $618.0–$642.0 million, and diluted EPS of $17.25–$17.95.
Medpace (Nasdaq: MEDP) will report its Q2 2026 financial results after market close on Wednesday, July 22, 2026. A conference call to discuss the results will be held on Thursday, July 23, 2026 at 9:00 a.m. ET, with webcast and replay via the Investors section of its website.
Medpace (Nasdaq: MEDP) reported first quarter 2026 revenue of $706.6M, up 26.5% year-over-year, GAAP net income of $123.9M ($4.28 diluted), and EBITDA of $149.4M (21.1% margin). Backlog totaled $2,929.2M. Cash and equivalents were $652.7M and operating cash flow was $151.8M.
Full-year 2026 guidance: revenue $2.755B–$2.855B, GAAP net income $487M–$511M, and EBITDA $605M–$635M. President Jesse Geiger will retire effective May 31, 2026.
Medpace (Nasdaq: MEDP) will report first quarter 2026 financial results after market close on April 22, 2026.
The company will host a conference call to discuss results on April 23, 2026 at 9:00 a.m. ET. Webcast, replay, and a supplemental slide presentation will be available in the Investors section at investor.medpace.com. Telephone participants must register in advance.
Summary not available.
Medpace (Nasdaq: MEDP) reported strong fourth-quarter and full-year 2025 results, driven by robust revenue growth and solid bookings.
Q4 revenue was $708.5M (+32.0% YoY) and GAAP net income was $135.1M ($4.67/diluted). Full-year 2025 revenue was $2,530.2M (+20.0% YoY) with GAAP net income of $451.1M ($15.28/diluted). The company repurchased 2,961,924 shares for $912.9M in 2025 and provided 2026 guidance of $2.755B–$2.855B revenue and GAAP net income of $487M–$511M.
Medpace (Nasdaq: MEDP) will report fourth quarter and fiscal year 2025 financial results after market close on Monday, February 9, 2026. The company will host a conference call to discuss results on Tuesday, February 10, 2026 at 9:00 a.m. ET.
Telephone participants must register in advance to receive a confirmation email with dial-in details and a unique PIN. A live webcast, supplemental slide presentation, and a replay (available ~one hour after the call ends) will be available in the Investors section at investor.medpace.com.
Medpace (Nasdaq: MEDP) reported third quarter 2025 revenue of $659.9M, up 23.7% YoY, with net new business awards of $789.6M (+47.9%) and a net book-to-bill of 1.20x. GAAP net income was $111.1M or $3.86 per diluted share; net income margin was 16.8% versus 18.1% a year ago. EBITDA rose 24.9% to $148.4M (22.5% margin). Cash and equivalents were $285.4M and operating cash flow in Q3 was $246.2M. Year-to-date share repurchases totaled 2,961,924 shares for $912.9M, with $821.7M remaining on the buyback. Full‑year 2025 guidance: revenue $2.48–2.53B, GAAP net income $431–439M, EBITDA $545–555M.